Quality Indicators as a Tool in Improving the Introduction of New Medicines

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Basic & Clinical Pharmacology & Toxicology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcpt.12295PMID 25052464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

  2014cited by this paper
• A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries

  2014cited by this paper
• Are payers treating orphan drugs differently?

  2014cited by this paper
• The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

  2014cited by this paper
• Dabigatran – an exemplar case history demonstrating the need for comprehensive models to optimise the use of new drugs

  2014cited by this paper
• Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

  2013cited by this paper
• Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

  2013cited by this paper
• priority Medicines for Europe and the World: 2013 update

  2013cited by this paper
• Personalising health care: feasibility and future implications focusing on a payers’ perspective

  2013cited by this paper
• Managed entry agreements for pharmaceuticals: the European experience

  2013cited by this paper
• Health authority perspective on biosimilars

  2013cited by this paper
• Inequities in access to biologic and synthetic DMARDs across 46 European countries

  2013cited by this paper
• Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs

  2013cited by this paper
• Personalizing healthcare: from genetics through payment to improving care?

  2013cited by this paper
• The intriguing future of pharmacoepidemiology

  2013cited by this paper
• A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation

  2013cited by this paper
• Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.

  2013cited by this paper
• Effect of financial incentives on incentivised and non-incentivised clinical activities: longitudinal analysis of data from the UK Quality and Outcomes Framework

  2013cited by this paper
• Rationalizing Prescribing for Older Patients with Multimorbidity: Considering Time to Benefit

  2013cited by this paper
• Personalizing health care: feasibility and future implications

  2013cited by this paper
• Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi‐Automatic Methods Using Anti‐TNF Therapy as Model

  2013cited by this paper
• Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study.

  2013cited by this paper
• The Nordic prescription databases as a resource for pharmacoepidemiological research—a literature review

  2013cited by this paper
• The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

  2013cited by this paper
• The most transformative drugs of the past 25 years: a survey of physicians

  2013cited by this paper
• Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations

  2013cited by this paper
• Cancer drugs in the United States: Justum Pretium--the just price.

  2013cited by this paper
• Personalized medicine. New cystic fibrosis drug offers hope, at a price.

  2012cited by this paper
• New drugs and indications in 2011. France is better focused on patients' interests after the Mediator scandal, but stagnation elsewhere.

  2012cited by this paper
• Failure of clinical practice guidelines to meet institute of medicine standards: Two more decades of little, if any, progress.

  2012cited by this paper
• Improving the managed entry of new medicines: sharing experiences across Europe

  2012cited by this paper
• UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

  2012cited by this paper
• eHealth: individualisation of infliximab treatment and disease course via a self‐managed web‐based solution in Crohn's disease

  2012cited by this paper
• Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

  2012cited by this paper
• Implementing pay‐for‐performance in Australian primary care: lessons from the United Kingdom and the United States

  2011cited by this paper
• Framework and indicator testing protocol for developing and piloting quality indicators for the UK quality and outcomes framework

  2011cited by this paper
• Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

  2011cited by this paper
• Medication adherence: WHO cares?

  2011cited by this paper
• The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm.

  2011cited by this paper
• Identifying unintended consequences of quality indicators: a qualitative study

  2011cited by this paper
• Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009

  2011cited by this paper
• Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study

  2011cited by this paper
• Multiple strategies for quality improvement and patient safety—money alone is not the answer, nor is trust. Conclusions of the 6th EQuiP Invitational conference April 2011

  2011cited by this paper
• Pharmaceutical policies and the economic crisis 1 Pharmaceutical policy and the effects of the economic crisis : Lithuania

  2011cited by this paper
• Development of prescribing-safety indicators for GPs using the RAND Appropriateness Method.

  2011cited by this paper
• Einführung neuer Arzneimittel in europäische Gesundheitssysteme

  2010cited by this paper
• Cardiovascular and Smooth Muscle Pharmacology in the Next Decade

  2010cited by this paper
• Study protocol of effectiveness of a biopsychosocial multidisciplinary intervention in the evolution of non-speficic sub-acute low back pain in the working population: cluster randomised trial

  2010cited by this paper
• A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management

  2010cited by this paper
• Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

  2010cited by this paper
• Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment.

  2010cited by this paper
• Forecasting drug utilization and expenditure in a metropolitan health region

  2010cited by this paper
• Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes.

  2010cited by this paper
• Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications

  2010cited by this paper
• Implementing pay‐for‐performance in Australian primary care: lessons from the United Kingdom and the United States

  2010cited by this paper
• Effects of pay for performance on the quality of primary care in England.

  2009cited by this paper
• Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care.

  2009cited by this paper
• Informing disinvestment through cost-effectiveness modelling

  2009cited by this paper
• Soft regulations in pharmaceutical policy making

  2009cited by this paper
• Canadian Agency for Drugs and Technologies in Health

  2009cited by this paper
• Quality Measurement in Orthopaedics: The Purchasers’ View

  2009cited by this paper
• Unfilled Prescriptions of Medicare Beneficiaries: Prevalence, Reasons, and Types of Medicines Prescribed

  2008cited by this paper
• National Registries of Systemic Treatment for Psoriasis and the European ‘Psonet’ Initiative

  2008cited by this paper
• Industry Influence in the Creation of Pay‐for‐Performance Quality Measures

  2008cited by this paper
• Enhancing the rational use of new medicines across European health care systems

  2008cited by this paper
• Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions.

  2008cited by this paper
• Impact of financial incentives on clinical autonomy and internal motivation in primary care: ethnographic study

  2008cited by this paper
• The good indicators guide: understanding how to use and choose indicators

  2008cited by this paper
• European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe

  2007cited by this paper
• The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

  2007cited by this paper
• Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

  2007cited by this paper
• Effective chronic disease management: patients' perspectives on medication-related problems.

  2007cited by this paper
• Why don't patients take their medicine? Reasons and solutions in psychiatry †

  2007cited by this paper
• Performance measurement and equity

  2007cited by this paper
• The good indicators guide: understanding how to use and choose indicators

  2007cited by this paper
• Impact of financial incentives on clinical autonomy and internal motivation in primary care: ethnographic study

  2007cited by this paper
• Is it possible to measure prescribing quality using only prescription data?

  2006cited by this paper
• International diffusion of new health technologies: A ten-country analysis of six health technologies

  2006cited by this paper
• Templates for analysis of individual-level prescription data.

  2006cited by this paper
• Swedish registers to examine drug safety and clinical issues in RA

  2006cited by this paper
• The price of independence

  2006cited by this paper
• Collecting information on the quality of prescribing in primary care using semi-automatic data extraction from GPs' electronic medical records

  2005cited by this paper
• Budget impact analysis: review of the state of the art

  2005cited by this paper
• Inappropriate Medication Use Among Frail Elderly Inpatients

  2004cited by this paper
• Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004)

  2004cited by this paper
• Linking physicians' pay to the quality of care--a major experiment in the United kingdom.

  2004cited by this paper
• Priority medicines for Europe and the world

  2004cited by this paper
• Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

  2004cited by this paper
• Research methods used in developing and applying quality indicators in primary care

  2002cited by this paper
• What makes British general practitioners take part in a quality improvement scheme?

  2001cited by this paper
• Improving the quality of health care in the United Kingdom and the United States: a framework for change.

  2001cited by this paper
• The public release of performance data: what do we expect to gain? A review of the evidence.

  2000cited by this paper
• Testing the Validity of Cost-Effectiveness Models

  2000cited by this paper
• Defining quality of care.

  2000cited by this paper
• Drug discovery: a historical perspective.

  2000cited by this paper
• Evidence of self-report bias in assessing adherence to guidelines.

  1999cited by this paper
• Indicators of Quality in Health Care

  1997cited by this paper
• Methods for the economic evaluation of health care programmes

  1987cited by this paper
• The Definition of Quality and Approaches to Its Assessment.

  1981cited by this paper
• Explorations in Quality Assessment and Monitoring. Volume I: The Definitions of Quality and Approaches to its Assessment

  1981cited by this paper

• Analogues in Diabetes Management: Current and Future Prospects

  2025cites this paper
• Quality of Care for Hypertension in Primary Health Care in South Africa: Cross-Sectional Feasibility Study

  2025cites this paper
• Development of quality indicators for hypertension management at the primary health care level in South Africa

  2024cites this paper
• Current Antibiotic Use Among Hospitals in the sub-Saharan Africa Region; Findings and Implications

  2023cites this paper
• Current rates of purchasing of antibiotics without a prescription across sub-Saharan Africa; rationale and potential programmes to reduce inappropriate dispensing and resistance

  2023cites this paper
• Ongoing Strategies to Improve Antimicrobial Utilization in Hospitals across the Middle East and North Africa (MENA): Findings and Implications

  2023cites this paper
• Ongoing Efforts to Improve Antimicrobial Utilization in Hospitals among African Countries and Implications for the Future

  2022cites this paper
• Determinants of the Empiric Use of Antibiotics by General Practitioners in South Africa: Observational, Analytic, Cross-Sectional Study

  2022cites this paper
• The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future

  2021cites this paper
• Key Issues Surrounding Appropriate Antibiotic Use for Prevention of Surgical Site Infections in Low- and Middle-Income Countries: A Narrative Review and the Implications

  2021cites this paper
• Evidence-based public policy making for medicines across countries: findings and implications for the future.

  2021cites this paper
• Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future

  2021cites this paper
• Potential Strategies to Improve Antimicrobial Utilisation in Hospitals in Bangladesh Building on Experiences Across Developing Countries

  2021cites this paper
• Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions

  2020cites this paper
• Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

  2020cites this paper
• Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future

  2020cites this paper
• Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future

  2019cites this paper
• Strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries; findings and implications

  2019cites this paper
• Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries

  2019cites this paper
• Role of Health Technology Assessment in Pharmaceutical Market Access in Developed Countries

  2018cites this paper
• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

  2018cites this paper
• Analysis of new drugs registered in Brazil in view of the Unified Health System and the disease burden.

  2018cites this paper
• The Early Awareness and Alert System in Sweden: History and Current Status

  2017cites this paper
• Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements

  2017cites this paper
• Identificación de indicadores de resultado en salud en atención primaria. Una revisión de revisiones sistemáticas

  2017cites this paper
• [Payment to providers of health services in Bogotá].

  2017cites this paper
• Strategies for business capacity expansion in Jordanian pharmaceutical companies

  2017cites this paper
• Principles for Developing Clinical Quality Standards in Low and Middle Income Countries: A Guide

  2017cites this paper
• [Identification of health outcome indicators in Primary Care. A review of systematic reviews].

  2017cites this paper
• COMPARATIVE BIOAVAILABILITY ANALYSIS OF ORAL ALENDRONATE SODIUM FORMULATIONS IN PAKISTAN.

  2016cites this paper
• Initiatives among Authorities to Improve the Quality and Efficiency of Prescribing and the Implications

  2016influential citation
• Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

  2016cites this paper
• Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

  2016cites this paper
• Varenicline and Nicotine Patch Therapies in Young Adults Motivated to Quit Smoking: A Randomized, Placebo‐controlled, Prospective Study

  2016cites this paper
• EVALUATION OF DRUG USE INDICATORS FOR NON-COMMUNICABLE DISEASES IN PAKISTAN.

  2016cites this paper
• The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications

  2015cites this paper
• Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future

  2015cites this paper
• Ongoing Initiatives in China to Enhance Prescribing Efficiency: Impact and Proposals for Improvement

  2015cites this paper
• Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

  2015influential citation
• Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe

  2015cites this paper
• Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction.

  2014cites this paper